Q1 2026 Management view Chairman, President & CEO Dennis Lanfear said the strategy is built around LOQTORZI as “both a revenue generator” in nasopharyngeal cancer (NPC) and “a revenue multiplier” in ...
MarketBeat on MSN
Coherus Oncology Q1 earnings call highlights
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through ...
Well, thank you, Carrie, and thank you all for joining us this afternoon on our Q1 2026 quarterly call. Such as casdozoketug, which we are exploring in liver cancer, and which we are exploring across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results